Compare Cipla with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs IPCA LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA IPCA LABS CIPLA/
IPCA LABS
 
P/E (TTM) x 30.6 26.0 117.8% View Chart
P/BV x 4.3 5.2 83.0% View Chart
Dividend Yield % 0.5 0.4 123.1%  

Financials

 CIPLA   IPCA LABS
EQUITY SHARE DATA
    CIPLA
Mar-21
IPCA LABS
Mar-21
CIPLA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs8792,456 35.8%   
Low Rs4111,371 29.9%   
Sales per share (Unadj.) Rs237.6423.3 56.1%  
Earnings per share (Unadj.) Rs29.890.6 32.9%  
Cash flow per share (Unadj.) Rs43.0107.1 40.2%  
Dividends per share (Unadj.) Rs5.004.00 125.0%  
Avg Dividend yield %0.80.2 371.1%  
Book value per share (Unadj.) Rs226.7370.6 61.2%  
Shares outstanding (eoy) m806.46126.85 635.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.74.5 60.0%   
Avg P/E ratio x21.621.1 102.5%  
P/CF ratio (eoy) x15.017.9 83.8%  
Price / Book Value ratio x2.85.2 55.1%  
Dividend payout %16.84.4 380.2%   
Avg Mkt Cap Rs m519,826242,728 214.2%   
No. of employees `000NANA-   
Total wages/salary Rs m32,51810,136 320.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m191,59653,699 356.8%  
Other income Rs m2,6981,292 208.8%   
Total revenues Rs m194,29454,991 353.3%   
Gross profit Rs m42,48714,812 286.8%  
Depreciation Rs m10,6772,092 510.4%   
Interest Rs m1,607123 1,309.7%   
Profit before tax Rs m32,90113,890 236.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,8882,401 370.1%   
Profit after tax Rs m24,01311,488 209.0%  
Gross profit margin %22.227.6 80.4%  
Effective tax rate %27.017.3 156.2%   
Net profit margin %12.521.4 58.6%  
BALANCE SHEET DATA
Current assets Rs m132,09534,370 384.3%   
Current liabilities Rs m45,91611,331 405.2%   
Net working cap to sales %45.042.9 104.8%  
Current ratio x2.93.0 94.8%  
Inventory Days Days6849 139.0%  
Debtors Days Days76 119.0%  
Net fixed assets Rs m116,27726,295 442.2%   
Share capital Rs m1,613254 635.8%   
"Free" reserves Rs m181,23246,763 387.6%   
Net worth Rs m182,84447,017 388.9%   
Long term debt Rs m12,028365 3,291.6%   
Total assets Rs m248,37260,664 409.4%  
Interest coverage x21.5114.2 18.8%   
Debt to equity ratio x0.10 846.4%  
Sales to assets ratio x0.80.9 87.1%   
Return on assets %10.319.1 53.9%  
Return on equity %13.124.4 53.7%  
Return on capital %17.729.6 59.9%  
Exports to sales %31.30-   
Imports to sales %10.90-   
Exports (fob) Rs m59,951NA-   
Imports (cif) Rs m20,911NA-   
Fx inflow Rs m68,05127,172 250.4%   
Fx outflow Rs m20,9117,949 263.1%   
Net fx Rs m47,14019,223 245.2%   
CASH FLOW
From Operations Rs m37,55210,901 344.5%  
From Investments Rs m-23,872-5,207 458.5%  
From Financial Activity Rs m-13,299-3,058 434.9%  
Net Cashflow Rs m5092,636 19.3%  

Share Holding

Indian Promoters % 13.5 46.3 29.1%  
Foreign collaborators % 20.1 0.0 -  
Indian inst/Mut Fund % 48.6 44.0 110.6%  
FIIs % 26.6 11.0 241.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 53.7 123.6%  
Shareholders   418,584 115,335 362.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 24, 2022 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS